The myokine FGF21 associates with enhanced survival in ALS and mitigates stress-induced cytotoxicity
Amyotrophic lateral sclerosis (ALS) is an age-related and fatal neurodegenerative disease characterized by progressive muscle weakness. There is marked heterogeneity in clinical presentation, progression, and pathophysiology with only modest treatments to slow disease progression. Molecular markers...
Saved in:
Published in | bioRxiv |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Cold Spring Harbor Laboratory
14.09.2024
|
Online Access | Get full text |
Cover
Loading…
Abstract | Amyotrophic lateral sclerosis (ALS) is an age-related and fatal neurodegenerative disease characterized by progressive muscle weakness. There is marked heterogeneity in clinical presentation, progression, and pathophysiology with only modest treatments to slow disease progression. Molecular markers that provide insight into this heterogeneity are crucial for clinical management and identification of new therapeutic targets. In a prior muscle miRNA sequencing investigation, we identified altered FGF pathways in ALS muscle, leading us to investigate FGF21. We analyzed human ALS muscle biopsy samples and found a large increase in FGF21 expression with localization to atrophic myofibers and surrounding endomysium. A concomitant increase in FGF21 was detected in ALS spinal cords which correlated with muscle levels. FGF21 was increased in the SOD1
mouse beginning in presymptomatic stages. In parallel, there was dysregulation of the co-receptor, β-Klotho. Plasma FGF21 levels were increased and high levels correlated with slower disease progression, prolonged survival, and increased body mass index. In NSC-34 motor neurons and C2C12 muscle cells expressing SOD1
or exposed to oxidative stress, ectopic FGF21 mitigated loss of cell viability. In summary, FGF21 is a novel biomarker in ALS that correlates with slower disease progression and exerts trophic effects under conditions of cellular stress. |
---|---|
AbstractList | Amyotrophic lateral sclerosis (ALS) is an age-related and fatal neurodegenerative disease characterized by progressive muscle weakness. There is marked heterogeneity in clinical presentation, progression, and pathophysiology with only modest treatments to slow disease progression. Molecular markers that provide insight into this heterogeneity are crucial for clinical management and identification of new therapeutic targets. In a prior muscle miRNA sequencing investigation, we identified altered FGF pathways in ALS muscle, leading us to investigate FGF21. We analyzed human ALS muscle biopsy samples and found a large increase in FGF21 expression with localization to atrophic myofibers and surrounding endomysium. A concomitant increase in FGF21 was detected in ALS spinal cords which correlated with muscle levels. FGF21 was increased in the SOD1
G93A
mouse beginning in presymptomatic stages. In parallel, there was dysregulation of the co-receptor, β-Klotho. Plasma FGF21 levels were increased and high levels correlated with slower disease progression, prolonged survival, and increased body mass index. In NSC-34 motor neurons and C2C12 muscle cells expressing SOD1
G93A
or exposed to oxidative stress, ectopic FGF21 mitigated loss of cell viability. In summary, FGF21 is a novel biomarker in ALS that correlates with slower disease progression and exerts trophic effects under conditions of cellular stress. Amyotrophic lateral sclerosis (ALS) is an age-related and fatal neurodegenerative disease characterized by progressive muscle weakness. There is marked heterogeneity in clinical presentation, progression, and pathophysiology with only modest treatments to slow disease progression. Molecular markers that provide insight into this heterogeneity are crucial for clinical management and identification of new therapeutic targets. In a prior muscle miRNA sequencing investigation, we identified altered FGF pathways in ALS muscle, leading us to investigate FGF21. We analyzed human ALS muscle biopsy samples and found a large increase in FGF21 expression with localization to atrophic myofibers and surrounding endomysium. A concomitant increase in FGF21 was detected in ALS spinal cords which correlated with muscle levels. FGF21 was increased in the SOD1 mouse beginning in presymptomatic stages. In parallel, there was dysregulation of the co-receptor, β-Klotho. Plasma FGF21 levels were increased and high levels correlated with slower disease progression, prolonged survival, and increased body mass index. In NSC-34 motor neurons and C2C12 muscle cells expressing SOD1 or exposed to oxidative stress, ectopic FGF21 mitigated loss of cell viability. In summary, FGF21 is a novel biomarker in ALS that correlates with slower disease progression and exerts trophic effects under conditions of cellular stress. Amyotrophic lateral sclerosis (ALS) is an age-related and fatal neurodegenerative disease characterized by progressive muscle weakness. There is marked heterogeneity in clinical presentation, progression, and pathophysiology with only modest treatments to slow disease progression. Molecular markers that provide insight into this heterogeneity are crucial for clinical management and identification of new therapeutic targets. In a prior muscle miRNA sequencing investigation, we identified altered FGF pathways in ALS muscle, leading us to investigate FGF21. We analyzed human ALS muscle biopsy samples and found a large increase in FGF21 expression with localization to atrophic myofibers and surrounding endomysium. A concomitant increase in FGF21 was detected in ALS spinal cords which correlated with muscle levels. FGF21 was increased in the SOD1G93A mouse beginning in presymptomatic stages. In parallel, there was dysregulation of the co-receptor, β-Klotho. Plasma FGF21 levels were increased and high levels correlated with slower disease progression, prolonged survival, and increased body mass index. In NSC-34 motor neurons and C2C12 muscle cells expressing SOD1G93A or exposed to oxidative stress, ectopic FGF21 mitigated loss of cell viability. In summary, FGF21 is a novel biomarker in ALS that correlates with slower disease progression and exerts trophic effects under conditions of cellular stress.Amyotrophic lateral sclerosis (ALS) is an age-related and fatal neurodegenerative disease characterized by progressive muscle weakness. There is marked heterogeneity in clinical presentation, progression, and pathophysiology with only modest treatments to slow disease progression. Molecular markers that provide insight into this heterogeneity are crucial for clinical management and identification of new therapeutic targets. In a prior muscle miRNA sequencing investigation, we identified altered FGF pathways in ALS muscle, leading us to investigate FGF21. We analyzed human ALS muscle biopsy samples and found a large increase in FGF21 expression with localization to atrophic myofibers and surrounding endomysium. A concomitant increase in FGF21 was detected in ALS spinal cords which correlated with muscle levels. FGF21 was increased in the SOD1G93A mouse beginning in presymptomatic stages. In parallel, there was dysregulation of the co-receptor, β-Klotho. Plasma FGF21 levels were increased and high levels correlated with slower disease progression, prolonged survival, and increased body mass index. In NSC-34 motor neurons and C2C12 muscle cells expressing SOD1G93A or exposed to oxidative stress, ectopic FGF21 mitigated loss of cell viability. In summary, FGF21 is a novel biomarker in ALS that correlates with slower disease progression and exerts trophic effects under conditions of cellular stress. |
Author | Si, Ying Smith, Reed Jiang, Nan Velic, Emina Horvat Salgado, Juliana S Silva Pereira, Joao D Tavares Da Kazamel, Mohamed Thalacker-Mercer, Anna Smith, Katherine A Guha, Abhishek Singh, Brijesh K Ho, Ritchie Andrabi, Shaida A Agrawal, Manasi King, Peter H |
Author_xml | – sequence: 1 givenname: Abhishek orcidid: 0000-0003-2767-9941 surname: Guha fullname: Guha, Abhishek – sequence: 2 givenname: Ying surname: Si fullname: Si, Ying – sequence: 3 givenname: Reed surname: Smith fullname: Smith, Reed – sequence: 4 givenname: Mohamed surname: Kazamel fullname: Kazamel, Mohamed – sequence: 5 givenname: Nan surname: Jiang fullname: Jiang, Nan – sequence: 6 givenname: Katherine A surname: Smith fullname: Smith, Katherine A – sequence: 7 givenname: Anna orcidid: 0000-0002-9124-7927 surname: Thalacker-Mercer fullname: Thalacker-Mercer, Anna – sequence: 8 givenname: Brijesh K surname: Singh fullname: Singh, Brijesh K – sequence: 9 givenname: Ritchie orcidid: 0000-0003-1496-4436 surname: Ho fullname: Ho, Ritchie – sequence: 10 givenname: Shaida A surname: Andrabi fullname: Andrabi, Shaida A – sequence: 11 givenname: Joao D Tavares Da surname: Silva Pereira fullname: Silva Pereira, Joao D Tavares Da – sequence: 12 givenname: Juliana S surname: Salgado fullname: Salgado, Juliana S – sequence: 13 givenname: Manasi surname: Agrawal fullname: Agrawal, Manasi – sequence: 14 givenname: Emina Horvat surname: Velic fullname: Velic, Emina Horvat – sequence: 15 givenname: Peter H orcidid: 0000-0001-9391-7464 surname: King fullname: King, Peter H |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39314333$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkMtOwzAQRS0E4v0BbJCXbFI84zSJVwghCkiVWADryLUn1JDYJXYK_XvKU7CaGd2jc6XZY5s-eGLsCMQIQMApCsxHQq2PUQFQKLnBdrFQmFUoxpt_9h12GOOTEAJVAbLMt9mOVBJyKeUus_dz4t0qPDtPfHI1QeA6xmCcThT5q0tzTn6uvSHL49Av3VK33Hl-Pr3j2lveueQeP9mYeooxc94OH7BZpZDCmzMurQ7YVqPbSIffc589TC7vL66z6e3VzcX5NFvAeCyzylaCUFBORou8sbNZQ40wgDnoppK2LISqUBa2QqUlajRAOBOQgx0jAsp9dvblXQyzjqwhn3rd1ovedbpf1UG7-n_i3bx-DMsa1g4lyg_DybehDy8DxVR3LhpqW-0pDLGWIKqyyFVRrtHjv2W_LT-_le9tvH9Q |
ContentType | Journal Article |
DBID | NPM 7X8 5PM |
DOI | 10.1101/2024.09.11.611693 |
DatabaseName | PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | PubMed MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 2692-8205 |
ExternalDocumentID | 39314333 |
Genre | Journal Article Preprint |
GrantInformation_xml | – fundername: NINDS NIH HHS grantid: R01 NS092651 – fundername: BLRD VA grantid: I01 BX006231 – fundername: NINDS NIH HHS grantid: R21 NS111275 – fundername: BLRD VA grantid: I01 BX002466 |
GroupedDBID | 8FE 8FH AFKRA ALMA_UNASSIGNED_HOLDINGS BBNVY BENPR BHPHI HCIFZ LK8 M7P NPM NQS PIMPY PROAC RHI 7X8 5PM |
ID | FETCH-LOGICAL-p1553-8d80e20e4eca04fdbbfef0c1241af83d76098236d829a32a2c1e2b0141d522123 |
ISSN | 2692-8205 |
IngestDate | Wed Sep 25 09:19:51 EDT 2024 Mon Sep 30 17:00:52 EDT 2024 Fri Oct 18 08:54:35 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | English |
License | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-p1553-8d80e20e4eca04fdbbfef0c1241af83d76098236d829a32a2c1e2b0141d522123 |
Notes | ObjectType-Working Paper/Pre-Print-3 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0003-2767-9941 0000-0002-9124-7927 0000-0001-9391-7464 0000-0003-1496-4436 |
OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC11419072 |
PMID | 39314333 |
PQID | 3108764967 |
PQPubID | 23479 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_11419072 proquest_miscellaneous_3108764967 pubmed_primary_39314333 |
PublicationCentury | 2000 |
PublicationDate | 2024-Sep-14 20240914 |
PublicationDateYYYYMMDD | 2024-09-14 |
PublicationDate_xml | – month: 09 year: 2024 text: 2024-Sep-14 day: 14 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | bioRxiv |
PublicationTitleAlternate | bioRxiv |
PublicationYear | 2024 |
Publisher | Cold Spring Harbor Laboratory |
Publisher_xml | – name: Cold Spring Harbor Laboratory |
SSID | ssj0002961374 |
Score | 1.9381105 |
Snippet | Amyotrophic lateral sclerosis (ALS) is an age-related and fatal neurodegenerative disease characterized by progressive muscle weakness. There is marked... |
SourceID | pubmedcentral proquest pubmed |
SourceType | Open Access Repository Aggregation Database Index Database |
Title | The myokine FGF21 associates with enhanced survival in ALS and mitigates stress-induced cytotoxicity |
URI | https://www.ncbi.nlm.nih.gov/pubmed/39314333 https://www.proquest.com/docview/3108764967/abstract/ https://pubmed.ncbi.nlm.nih.gov/PMC11419072 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBdbykZfxr6XfaHB3oozW5Yt6zEbzcpYy0hb6J6CvkzMiB1WuzT963eSbCfpMtj2YhtblkA_cbrT3e8OofewJ8YJFWmg0wgMFE3zgNOMB1xpHSqZSJ1ZvvPxSXp0Tr9cJBfrUnKOXVLLkbrZySv5H1ThHeBqWbL_gGzfKbyAZ8AXroAwXP8a48Wq-mE1xcnnCYkORDvbpmWtmXLuXfyXDciEK5dh42D89dT5DBaFS7ABbT1jJAD7vLGN1aqu6uq6UEW95fWVRTW9Lq76mJ3Ge4vGcm4j63vOz6mLEPjebYqb5zdT05KprIwXN2LhgwSOqzk86s0jCEJtvISnfo6ME1Uk5SBXiSNQ7xDKrhiA_dGmlI2iESyL1NdF3ABpuXAoxTwGFc4nx7iVCbv7dBftEcaTZID2Ph6efJv2Z2qEg3LCaOu8hmE__DboPrrfdbPLprgdGruha5w9RA9aIwGPPeKP0B1TPkb3fNnQ1ROkAXfc4o4d7niNO7a44w533OGOixID7hhwxz3ueBt3vIn7U3Q-OTz7dBS01TKCpa39FGQ6Cw0JDTVKhDTXUuYmDxXob5HIs1izNOS2ur3OCBcxEURFhkgb56tBBwcF5hkalFVpXiAs4jSWLM85_EY1GOiMwI0lsEkzRZgaonfdzM1AGlkXkyhN1VzOwFiA7ZXylA3Rcz-Ts6VPmzLr5n2Isq057hvYTOfbX8pi7jKeg9EOiisjL__Y6Su0v16Zr9Gg_tmYN6Au1vJtu0p-AT3Uazw |
link.rule.ids | 230,315,786,790,891,27955,27956,33778 |
linkProvider | ProQuest |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+myokine+FGF21+associates+with+enhanced+survival+in+ALS+and+mitigates+stress-induced+cytotoxicity&rft.jtitle=bioRxiv&rft.au=Guha%2C+Abhishek&rft.au=Si%2C+Ying&rft.au=Smith%2C+Reed&rft.au=Kazamel%2C+Mohamed&rft.date=2024-09-14&rft.eissn=2692-8205&rft_id=info:doi/10.1101%2F2024.09.11.611693&rft_id=info%3Apmid%2F39314333&rft.externalDocID=39314333 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2692-8205&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2692-8205&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2692-8205&client=summon |